Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy.
You will receive photon radiation therapy. This type of radiation is similar to the radiation you have already had. Conformal radiotherapy or intensity modulated radiotherapy (IMRT) will be used to try to treat the tumor while affecting as little of the surrounding normal tissue as possible.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma|
- Optimal Dose Level Among Three Radiation Therapy (RT) Dose Levels [ Time Frame: 1 month after radiation therapy ] [ Designated as safety issue: Yes ]Optimal dose level among three RT dose levels, defined in terms of the biologically equivalent dose (BED). The BED is given by the formula BED = (Total Dose)*(1 + d/3), denoting d = dose/fraction, with the constant 3 corresponding to brain tissue.
|Study Start Date:||December 2011|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Experimental: Radiation Therapy
Starting dose of 24 Gray (Gy) in 2 Gy fractions.
Radiation: Radiation Therapy
Starting Dose 24 Gy in 2 Gy fractions.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01469247
|Contact: Mara Castaneda, RN||713-745-5129|
|Contact: Larae Eng, RN||713-563-5919|
|United States, Florida|
|Orlando, Florida, United States, 32806|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Anita Mahajan, MD||M.D. Anderson Cancer Center|